Letter
Full Access
Reply: To the editor
Giampiero Pasero MD, Ettore Marubini PhD, Francesco Priolo MD,
Francesco Priolo MD
“Sacro Cuore” University Rome, Italy (on behalf of GRISAR)
Search for more papers by this authorGiampiero Pasero MD, Ettore Marubini PhD, Francesco Priolo MD,
Francesco Priolo MD
“Sacro Cuore” University Rome, Italy (on behalf of GRISAR)
Search for more papers by this authorNo abstract is available for this article.
References
- 1 Felson DT, Anderson JJ, Meenan RF: The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 33: 1449–1461, 1990
- 2 Pincus T: Rheumatoid arthritis: disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 41: 1037–1041, 1988
- 3 Wolfe F, Hawley DJ, Cathey MA: Termination of slow-acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 17: 994–1002, 1990
- 4 Schwartz D, Flamant R, Lellouch J: L'Essai Thérapeutique Chez l'Homme. Paris, Ed Flammarion Med Sci, 1970
- 5 Möttönen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo-Repo M: Outcome in patients with early rheumatoid arthritis treated according to the “sawtooth” strategy. Arthritis Rheum 39: 996–1005, 1996
- 6 Paulus HE, Bulpitt KJ: DC-ART classification: review of relevant clinical studies. J Rheumatol 21 (Suppl 41): 8–22, 1994
- 7
Nordstrom DM,
West SG,
Andersen PA,
Sharp JT:
Pulse methotrexate therapy in rheumatoid arthritis: a controlled prospective roentgenographic study.
Ann Intern Med
107:
797–801,
1991
10.7326/0003-4819-107-6-797 Google Scholar
- 8 Jeurissen MEC, Boerbooms AMT, van de Putte LBA, Doesburg WH, Lemmens AM: Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. Ann Intern Med 114: 999–1004, 1991
- 9 Weinblatt ME, Polisson R, Blotner SD, Sosmand JL, Aliabadi P, Baker N, Weissman BN: The effects of drug therapy on radio-graphic progression of rheumatoid arthritis: results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 36: 613–619, 1993
- 10 López-Méndez A, Daniel WW, Reading JC, Ward JR, Alarcón GS: Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the Cooperative Systematic Studies of the Rheumatic Diseases Program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 36: 1364–1369, 1993
- 11 Herbon G, Rau R, Menninger H, Ezhardt D, Schmitt J: Data of two years of the comparative study of methotrexate/aurathiomalate in 102 patients. Z Rheumatol 51: 163–171, 1992
- 12 Alarcón GS, López-Méndez A, Walter J, Boerbooms AMT, Russell AS, Furst DE, Rau R, Drosos AA, Bartolucci AA: Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol 19: 1868–1873, 1992
- 13 Van der Heide A, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, van Booma-Frankfort C, van der Veen MJ, Haaen HCM, Hofman DM: The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 124: 699–707, 1996
- 14 Furst DE: Should methotrexate be used to treat early rheumatoid arthritis? Semin Arthritis Rheum 23 (Suppl 2): 39–43, 1994
- 15 Sharp JT, Wolfe F, Corbett M, Isomaki H, Mitchell DM, Furst DE, Sibley J, Shipley M: Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test modification? Ann Rheum Dis 52: 332–337, 1993
